A method for the in vitro or ex vivo assessment of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, including measuring the level of expression, in a biological sample obtained from said patient, of at least one expression product of the VEGFR2 gene.

Disclosed are compositions and methods of a microplate-based assay related to the field of thrombosis diagnosis, therapeutic screening, and drug development platforms.

Recombinant tissue plasminogen activator (tPA) is a lytic medication in wide use to treat thrombotic disorders such as stroke, myocardial infarction (MI), and pulmonary embolism (PE). It is also used off-label for the treatment of deep venous thrombosis (DVT) and acute peripheral arterial thrombosis/embolism. It has been shown in multiple studies that in approximately 25% of the individuals receiving the treatment the drug is ineffective. Start of the tPA treatment for these patients results in delay of start of alternate treatment for these patients which may be life saving for them. In the past there has been no test to find the effectiveness of the treatment and identify the individuals for whom the treatment will be ineffective. What is disclosed is a method of testing for effectiveness of the tPA treatment, that is testing for thrombolytic resistance, using a sample of the individual's blood via coagulation analysis.